drugset
drugset / Trial / NCT06492291

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291 ↗

Phase 3 Active not recruiting 3000 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

This is an extension study to evaluate the longer-term safety and efficacy of enlicitide decanoate in adults with hypercholesterolemia who completed either study MK-0616-013 (NCT05952856), study MK-0616-017 (NCT05952869), or study MK-0616-018 (NCT06450366).

Timeline

Start
2024-08-05
Primary completion
2028-10-13
Completion
2028-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Enlicitide Decanoate Unknown 20 mg Oral

Indications

No indication recorded.